相似文献
1
Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?
Ther Adv Med Oncol. 2010 Sep;2(5):331-42. doi: 10.1177/1758834010376301.
2
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD008941. doi: 10.1002/14651858.CD008941.pub2.
3
The role of antiangiogenetic agents in the treatment of breast cancer.
Curr Med Chem. 2011;18(33):5022-32. doi: 10.2174/092986711797636072.
4
Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Curr Med Chem. 2006;13(16):1845-57. doi: 10.2174/092986706777585059.
5
Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.
World J Gastroenterol. 2013 Aug 21;19(31):5051-60. doi: 10.3748/wjg.v19.i31.5051.
6
Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.
Invest New Drugs. 2013 Feb;31(1):1-13. doi: 10.1007/s10637-012-9817-7. Epub 2012 Apr 27.
7
Integration of novel agents in the treatment of colorectal cancer.
Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. doi: 10.1007/s00280-004-0884-0.
8
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
BioDrugs. 2009;23(5):289-304. doi: 10.2165/11317600-000000000-00000.
9
Bevacizumab in the treatment of breast cancer.
Cancer Treat Rev. 2010 Feb;36(1):75-82. doi: 10.1016/j.ctrv.2009.10.007. Epub 2009 Nov 22.
10
The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Health Technol Assess. 2013 Apr;17(14):1-237. doi: 10.3310/hta17140.
引用本文的文献
1
Short-term study on in-use stability of opened bevacizumab biosimilar PF-06439535 vials.
Eur J Hosp Pharm. 2022 Jul 19;31(2):135-42. doi: 10.1136/ejhpharm-2021-003198.
2
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
J Cell Physiol. 2017 Jun;232(6):1571-1578. doi: 10.1002/jcp.25685. Epub 2016 Nov 30.
3
Vaccines targeting the neovasculature of tumors.
Vasc Cell. 2011 Mar 8;3(1):7. doi: 10.1186/2045-824X-3-7.
本文引用的文献
1
N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial.
Ann Oncol. 2013 Oct;24(10):2548-2554. doi: 10.1093/annonc/mdt213. Epub 2013 Jun 24.
2
A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group.
Ann Oncol. 2012 Feb;23(2):331-7. doi: 10.1093/annonc/mdr344. Epub 2011 Aug 4.
3
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).
Ann Oncol. 2011 Jan;22(1):80-85. doi: 10.1093/annonc/mdq319. Epub 2010 Jul 1.
4
Pathways mediating VEGF-independent tumor angiogenesis.
Cytokine Growth Factor Rev. 2010 Feb;21(1):21-6. doi: 10.1016/j.cytogfr.2009.11.003. Epub 2009 Dec 11.
5
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab.
Clin Cancer Res. 2009 Dec 15;15(24):7652-7657. doi: 10.1158/1078-0432.CCR-09-1493.
6
North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.
Ann Oncol. 2010 Feb;21(2):269-274. doi: 10.1093/annonc/mdp512. Epub 2009 Nov 9.
7
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.
J Clin Oncol. 2010 Feb 1;28(4):628-33. doi: 10.1200/JCO.2009.21.8784. Epub 2009 Oct 19.
8
Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease.
Br J Cancer. 2009 Aug 18;101(4):666-72. doi: 10.1038/sj.bjc.6605196. Epub 2009 Jul 21.
9
VEGF kinase inhibitors: how do they cause hypertension?
Am J Physiol Regul Integr Comp Physiol. 2009 Jul;297(1):R1-5. doi: 10.1152/ajpregu.90502.2008. Epub 2009 May 13.
10
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers.
Clin Cancer Res. 2009 May 15;15(10):3583-90. doi: 10.1158/1078-0432.CCR-08-2917. Epub 2009 May 5.
Zotero 插件